ANT-GROUP-DIGITAL
3.11.2022 10:19:44 CET | Business Wire | Press release
Ant Group Digital Technologies, a digital technology provider under Ant Group, today unveiled its blockchain storage engine “LETUS” (Log-structured Efficient Trusted Universal Storage) at the Apsara Conference 2022 in Hangzhou.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221103005680/en/
Yan Ying, Technical Director of AntChain, unveiled the LETUS at the Apsara Conference (Photo: Business Wire)
LETUS, which was developed and designed by the AntChain team, will increase the effectiveness and lower the storage costs for blockchain networks.
Blockchain is a distributed peer-to-peer network, with each node storing data such as blocks and states. The LETUS storage engine is deployed at each blockchain node to provide trusted storage support. At the same time, LETUS has the advantages in performance, large scale workloads handling capability, cost, and resource efficiency through Smart Thermo-control Tiering and Boundary Scan Based Batch Pruning.
“As more and more digital assets are stored on the blockchain, storage capacity and efficiency has increasing impact on the overall performance of blockchain platforms, including transaction speeds and operational costs,” said Yan Ying, Technical Director of AntChain. “Compared to current mainstream industry solutions, LETUS can improve storage throughput by 15 times, reduce latency by 90%, and save disk bandwidth and space usage by 95% and 60%, respectively."
LETUS has already been deployed and running in Topnod, a digital collectibles platform powered by AntChain. It has helped the platform greatly improve performance and reduce storage costs by about 75%.
“For the many industries undergoing digital transformations, mutual trust between companies and customers is increasingly important. At Ant, we have been investing in research and development for blockchain and other digital technologies that help to increase both trust and security,” said Geoff Jiang, President of Digital Technology Business Group at Ant Group. “We remain focused on the technological breakthroughs that create a trusted digital network to improve industrial collaboration and allow us to use our innovative products and services to better serve the real economy.”
During the conference, Ant Group Digital Technologies also released the:
- 4.0 version of mPaaS, its one-stop mobile development solution;
- 2.0 version of its Morse MPC (Multi-party Computation) platform;
- 4.0 version of SOFAStack, its cloud-native PaaS platform;
- 4.0 version of OceanBase Community Edition, its distributed database; and
- other security products.
In the past two years, Ant Group Digital Technologies has also released a number of blockchain-related products and solutions, including:
- AntChain Station, the all-in-one workstation;
- Blockchain Transmission Network (BTN), a high-speed, long-distance blockchain communication technology;
- Module-as-a-Service (MaaS) integrated computing module for simplified blockchain deployment;
- FAIR, the data privacy collaboration platform; and
- T1 security chip, its self-developed blockchain-powered security chip.
Many of these cutting-edge solutions have been successfully deployed by Chery Automobile, Zhejiang Huatie Emergency Equipment Science and Technology and other industry partners.
Ant Group Digital Technologies
Ant Group Digital Technologies continues to promote the development and application of digital technology, introducing leading products like AntChain, OceanBase, SOFAStack, and mPaaS based on its expertise in blockchain, privacy computing, security technology, and distributed database. Ant Group Digital Technologies is committed to working with partners across different industries to support the small and medium-sized financial institutions in their digital transformation, enable SMEs in the service industry to operate digitally and facilitate digital collaboration across industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
